- Veriphi unveils working prototype of device to investors
- Veriphi updates investors on the results of recent hospital trials
- Veriphi lines up partnership deals, moving closer to commercial sales
This week’s Investor Evening, held at Veriphi’s harbourside offices, gave current and potential investors the opportunity to hear from the Veriphi team on the progress made over the past year. In that time, Veriphi has produced working prototypes of the device ready for commercial roll-out; shortened the verification time of drug-testing to less than 10 seconds; established formal dialogue with the US FDA and other compliance bodies; and relocated to larger offices.
Product development engineer Tom Boyens updated attendees on the recent hospital trails which are nearing completion, and demonstrated the analyser with different drugs and concentrations. Researcher Robbie Kerridge showed investors the laboratory where the team conducts experiments and collects training data and explained how Veriphi’s testing rigs work, while hardware engineer Dr. Kyle Pennington walked investors through the analyser’s technical details and operation. Veriphi’s IP manager Natalee Taylor explained the company’s adoption of ‘smart IP’, ensuring that the IP reflects Veriphi’s commercial strategy, and is proactive and reflective.
MD Greg Shanahan outlined the way forward for Veriphi – to realise commercial sales, establish domestic and international partnerships and build the next generation device to medical standards. The evening generated an engaging and informative dialogue between the Veriphi team and investors and we’re hoping it will lead to further investment.
The evening generated an engaging and informative dialogue between the Veriphi team and investors and we’re hoping it will lead to further interest and investment. So far, the Snowball Effect offer has raised more than $675,000 from 125 investors with the offer due to close next week.